Omega-3 fatty acids, subclinical atherosclerosis, and cardiovascular events: Implications for primary prevention.

ABSTRACT:

Background and aims

High-dose eicosapentaenoic acid (EPA) therapy was beneficial in high-risk patients without clinical cardiovascular disease (CVD). Whether higher plasma levels of EPA and docosahexaenoic acid (DHA) have similar benefits in those without subclinical CVD is unclear. We aim to evaluate the interplay between plasma omega-3 fatty acids and coronary artery calcium (CAC) in relation to CVD events.

Methods

We examined 6568 participants from the Multi-Ethnic Study of Atherosclerosis (MESA) with plasma EPA and DHA levels and CAC measured at baseline. The primary outcome was incident CVD events (myocardial infarction, angina, cardiac arrest, stroke, CVD death). Hazard ratios for the primary outcome were adjusted for potential confounder using Cox regression.

Resul

SUBMITTER: Alfaddagh A 

PROVIDER: S-EPMC10961178 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature